<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983942</url>
  </required_header>
  <id_info>
    <org_study_id>B0010</org_study_id>
    <nct_id>NCT02983942</nct_id>
  </id_info>
  <brief_title>Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma</brief_title>
  <official_title>Ketogenic Diet Adjunctive to High Dose Methotrexate Chemotherapy for Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketogenic diet has shown auxiliary effect on treatment of malignant tumors require high&#xD;
      glucose consumption. This study is designed to evaluate the safety and efficacy of ketogenic&#xD;
      diet adjunctive to high dose methotrexate(HD-MTX) chemotherapy for primary central nervous&#xD;
      system lymphoma (PCNSL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a pilot study of primary central nervous system(CNS) lymphoma patients, ketogenic diet was&#xD;
      given in adjunction with standard HD-MTX chemotherapy as interventional group; standard&#xD;
      HD-MTX is given with routine diet as control group. The primary endpoint is the safety of&#xD;
      ketogenic diet in PCNSL patients receiving chemotherapy, secondary endpoints include rate of&#xD;
      complete remission, remission time, rate of tumor relapse and overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Two years</time_frame>
    <description>The number and incidence (%) of treatment related adverse events among participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The chemosensitivity of tumor</measure>
    <time_frame>Two years</time_frame>
    <description>The rate of complete remission after treatment assessed according to serial contrast Magnetic Resonance Imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term effect of chemotherapy</measure>
    <time_frame>Two years</time_frame>
    <description>The average time from complete remission of tumor to relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Three years</time_frame>
    <description>Participants will be followed until reported death to calculate overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Two years</time_frame>
    <description>Short Form 36 Questionnaire will be used to assess patients' quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>ketogenic diet group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>routine diet group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ketogenic diet</intervention_name>
    <description>Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.</description>
    <arm_group_label>ketogenic diet group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Routine diet</intervention_name>
    <description>Routine diet is given without blood ketone requirement</description>
    <arm_group_label>routine diet group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70&#xD;
&#xD;
          2. Histopathologically confirmed PCNSL&#xD;
&#xD;
          3. No systemic involvement&#xD;
&#xD;
          4. Ability and willingness to sign informed consent&#xD;
&#xD;
          5. Normal liver and kidney function&#xD;
&#xD;
          6. Karnofsky Performance Score of 60 or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any systemic involvement of the tumor&#xD;
&#xD;
          2. Systemic illness or medical condition may pose additional risk, including cardiac,&#xD;
             metabolic or endocrine disorders; incompensated renal or liver disfunction; history of&#xD;
             renal calculi, hyperuricemia, hyper calcemia, mitochondrial disease, known disorder of&#xD;
             fatty acid metabolism, porphyria, carnitine deficiency and pancreatitis&#xD;
&#xD;
          3. Uncontrolled hyperlipidemia or hyperglycemia&#xD;
&#xD;
          4. Human immunodeficiency virus positive, or hepatitis C positive&#xD;
&#xD;
          5. Pregnancy of breastfeeding&#xD;
&#xD;
          6. Inability or unwillingness to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Song Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Song Lin, M.D.</last_name>
    <phone>861067096509</phone>
    <email>linsong2005@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chun Zeng, M.D.</last_name>
    <phone>861067096509</phone>
    <email>zengchun79@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Song Lin, M.D.</last_name>
      <phone>861067096509</phone>
      <email>linsong2005@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Chun Zeng, M.D.</last_name>
      <phone>861067096509</phone>
      <email>zengchun79@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Song Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ketogenic diet</keyword>
  <keyword>Primary Central Nervous System Lymphoma</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

